107 related articles for article (PubMed ID: 33713469)
1. The All Wales Medicines Strategy Group: 18 years' experience of a national medicines optimisation committee.
Haines K; Bracchi R; Lang R; Samuels K; Routledge PA
Br J Clin Pharmacol; 2021 Oct; 87(10):3961-3970. PubMed ID: 33713469
[TBL] [Abstract][Full Text] [Related]
2. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.
Varnava A; Bracchi R; Samuels K; Hughes DA; Routledge PA
Pharmacoeconomics; 2018 May; 36(5):613-624. PubMed ID: 29520603
[TBL] [Abstract][Full Text] [Related]
3. Estimated Versus Observed Expenditure Associated with Medicines Recommended by the All Wales Medicines Strategy Group.
Keeping S; Deslandes PN; Haines KE; Routledge PA
Pharmacoecon Open; 2019 Sep; 3(3):343-350. PubMed ID: 30656545
[TBL] [Abstract][Full Text] [Related]
4. Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.
Linley WG; Hughes DA
Pharmacoeconomics; 2013 Apr; 31(4):345-55. PubMed ID: 23516033
[TBL] [Abstract][Full Text] [Related]
5. Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors.
Linley WG; Hughes DA
Pharmacoeconomics; 2012 Sep; 30(9):779-94. PubMed ID: 22676385
[TBL] [Abstract][Full Text] [Related]
6. Opportunities for collaboration between pharmacists and clinical pharmacologists to support medicines optimisation in the UK.
Barnett NL
Br J Clin Pharmacol; 2019 Aug; 85(8):1666-1669. PubMed ID: 30986325
[TBL] [Abstract][Full Text] [Related]
7. Overview of the uptake and implementation of non-medical prescribing in Wales: a national survey.
Courtenay M; Khanfer R; Harries-Huntly G; Deslandes R; Gillespie D; Hodson K; Morris G; Pritchard A; Williams E
BMJ Open; 2017 Sep; 7(9):e015313. PubMed ID: 28947441
[TBL] [Abstract][Full Text] [Related]
8. A multi-stakeholder approach to the co-production of the research agenda for medicines optimisation.
Fellenor J; Britten N; Courtenay M; Payne RA; Valderas J; Denholm R; Duncan P; McCahon D; Tatnell L; Fitzgerald R; Warmoth K; Gillespie D; Turner K; Watson M
BMC Health Serv Res; 2021 Jan; 21(1):64. PubMed ID: 33441135
[TBL] [Abstract][Full Text] [Related]
9. Optimising the absorption of medicines.
Coulson J
Nurs Stand; 2020 Jul; 35(7):61-66. PubMed ID: 32638572
[TBL] [Abstract][Full Text] [Related]
10. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
11. Supporting patient access to medicines in community palliative care: on-line survey of health professionals' practice, perceived effectiveness and influencing factors.
Latter S; Campling N; Birtwistle J; Richardson A; Bennett MI; Ewings S; Meads D; Santer M
BMC Palliat Care; 2020 Sep; 19(1):148. PubMed ID: 32972414
[TBL] [Abstract][Full Text] [Related]
12. The Welsh Blood Service - 70 years of continuous change.
Poole GD
Transfus Med; 2017 Jun; 27(3):159-166. PubMed ID: 28271567
[TBL] [Abstract][Full Text] [Related]
13. Medicines Optimisation Assessment Tool (MOAT): a prognostic model to target hospital pharmacists' input to improve patient outcomes. Protocol for an observational study.
Geeson C; Wei L; Franklin BD
BMJ Open; 2017 Jun; 7(6):e017509. PubMed ID: 28615279
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of pharmacists' interventions to support medicines optimisation in patients with visual impairment.
Kentab BY; Barry HE; Al-Aqeel SA; Hughes CM
Int J Clin Pharm; 2019 Dec; 41(6):1400-1407. PubMed ID: 31531815
[TBL] [Abstract][Full Text] [Related]
15. Prescribing trends over time by non-medical independent prescribers in primary care settings across Wales (2011-2018): a secondary database analysis.
Alghamdi SSA; Hodson K; Deslandes P; Gillespie D; Haines K; Hulme E; Courtenay M; Deslandes R
BMJ Open; 2020 Oct; 10(10):e036379. PubMed ID: 33051229
[TBL] [Abstract][Full Text] [Related]
16. Building an effective medicines optimisation model: a health system approach.
Babar ZU
Int J Clin Pharm; 2024 Jun; ():. PubMed ID: 38896393
[TBL] [Abstract][Full Text] [Related]
17. Cross verification of prescribing trends through loop evaluation of physicians, patients and medical store personnel.
Husnain SZ; Bukhari NI; Hussain K; Babar ZU; Hashmi FK; Saleem Z; Salman M; Curley L
BMC Health Serv Res; 2019 May; 19(1):328. PubMed ID: 31118096
[TBL] [Abstract][Full Text] [Related]
18. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
19. Displaying medication costs on dispensing labels as a strategy to reduce wastage: views of the Welsh general public.
Yemm R; Jones C; Mitoko T
Integr Pharm Res Pract; 2017; 6():173-180. PubMed ID: 29354564
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
